In Vitro and In Vivo Effects of Palmaria palmata Derived Peptides on Glucose Metabolism
暂无分享,去创建一个
R. Fitzgerald | E. McSorley | P. Allsopp | P. Harnedy-Rothwell | C. McLaughlin | C. Mullen | F. O'Harte | V. Parthsarathy | Aurélien V. Le Gouic
[1] J. Whooley,et al. Identification and characterisation of peptides from a boarfish (Capros aper) protein hydrolysate displaying in vitro dipeptidyl peptidase-IV (DPP-IV) inhibitory and insulinotropic activity. , 2020, Food research international.
[2] J. Holst,et al. GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals. , 2020, The Journal of clinical endocrinology and metabolism.
[3] W. Atlee,et al. Update on type 2 diabetes mellitus drug treatment and drug usage-2020 , 2020 .
[4] Alyce M. Martin,et al. Mechanisms controlling hormone secretion in human gut and its relevance to metabolism , 2019, The Journal of endocrinology.
[5] C. Deacon. Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes , 2019, Front. Endocrinol..
[6] A. Nongonierma,et al. Features of dipeptidyl peptidase IV (DPP-IV) inhibitory peptides from dietary proteins. , 2019, Journal of food biochemistry.
[7] R. Gimeno,et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial , 2018, The Lancet.
[8] G. Cagney,et al. Casein Hydrolysate with Glycemic Control Properties: Evidence from Cells, Animal Models, and Humans. , 2018, Journal of Agricultural and Food Chemistry.
[9] P. Flatt,et al. Apelin-13 analogues show potent in vitro and in vivo insulinotropic and glucose lowering actions , 2018, Peptides.
[10] M. Tschöp,et al. Gut hormone polyagonists for the treatment of type 2 diabetes , 2018, Peptides.
[11] P. Dhulster,et al. Using Caco-2 cells as novel identification tool for food-derived DPP-IV inhibitors. , 2017, Food Research International.
[12] N. Irwin,et al. An enzymatically stable GIP/xenin hybrid peptide restores GIP sensitivity, enhances beta cell function and improves glucose homeostasis in high-fat-fed mice , 2016, Diabetologia.
[13] N. Irwin,et al. Biological Activity and Antidiabetic Potential of C-Terminal Octapeptide Fragments of the Gut-Derived Hormone Xenin , 2016, PloS one.
[14] N. Irwin,et al. New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disorders. , 2015, World journal of diabetes.
[15] P. Flatt,et al. Functional GIP receptors play a major role in islet compensatory response to high fat feeding in mice. , 2015, Biochimica et biophysica acta.
[16] N. Irwin,et al. A Novel CCK-8/GLP-1 Hybrid Peptide Exhibiting Prominent Insulinotropic, Glucose-Lowering, and Satiety Actions With Significant Therapeutic Potential in High-Fat–Fed Mice , 2015, Diabetes.
[17] P. Harnedy,et al. Purification and identification of dipeptidyl peptidase (DPP) IV inhibitory peptides from the macroalga Palmaria palmata. , 2015, Food chemistry.
[18] A. Cardador-Martínez,et al. Proteins and bioactive peptides , 2014 .
[19] T. Vilsbøll,et al. Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities. , 2014, European journal of internal medicine.
[20] P. Jakeman,et al. Food protein hydrolysates as a source of dipeptidyl peptidase IV inhibitory peptides for the management of type 2 diabetes , 2013, Proceedings of the Nutrition Society.
[21] J. Conlon,et al. Frog skin peptides (tigerinin-1R, magainin-AM1, -AM2, CPF-AM1, and PGla-AM1) stimulate secretion of glucagon-like peptide 1 (GLP-1) by GLUTag cells. , 2013, Biochemical and biophysical research communications.
[22] J. Holst,et al. Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes , 2011, Diabetes Care.
[23] Lorraine Brennan,et al. Amino Acid Metabolism, β-Cell Function, and Diabetes , 2006, Diabetes.
[24] M. Krebs,et al. Effects of dietary protein on glucose homeostasis , 2006, Current opinion in clinical nutrition and metabolic care.
[25] P. Flatt,et al. Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents. , 2004, Current pharmaceutical design.
[26] C. Bailey,et al. Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice , 1981, Diabetologia.
[27] R. Pederson,et al. Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. , 2003, Endocrinology.
[28] R. Pederson,et al. Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. , 2003, Endocrinology.
[29] Y. Seino,et al. Gastric inhibitory polypeptide activates MAP kinase through the wortmannin-sensitive and -insensitive pathways. , 1997, Biochemical and biophysical research communications.
[30] E. Ah-Sing,et al. Characterization of a Novel Glucose-Responsive Insulin-Secreting Cell Line, BRIN-BD11, Produced by Electrofusion , 1996, Diabetes.